Teva Pharmaceutical Expects 2024 Revenues Of $16.0B-$16.4B Versus Prior Guidance Of $15.7B-$16.3B And Consensus Of $16.012B
Author: Benzinga Newsdesk | July 31, 2024 07:06am
Outlook for 2024 Non-GAAP Results
| $ billions, except EPS or as noted |
July 2024 Outlook |
January 2024 Outlook |
| Revenues* |
$16.0 - $16.4 |
$15.7 - $16.3 |
| AUSTEDO ($m)* |
~1,600 |
~1,500 |
| AJOVY ($m)* |
~500 |
~500 |
| UZEDY ($m)* |
~80 |
~80 |
| COPAXONE ($m)* |
~450 |
~400 |
| Operating Income |
4.1 - 4.5 |
4.0 - 4.5 |
| Adjusted EBITDA |
4.6 - 5.0 |
4.5 - 5.0 |
| Finance Expenses ($m) |
~1,000 |
~1,000 |
| Tax Rate |
14% - 17% |
14% - 17% |
| Diluted EPS ($) |
2.30 - 2.50 |
2.20 - 2.50 |
| Free Cash Flow** |
1.7 - 2.0 |
1.7 - 2.0 |
| CAPEX* |
~0.5 |
~0.5 |
| Foreign Exchange |
Volatile swings in FX can negatively impact revenue and income |
Posted In: TEVA
